search
Back to results

A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
DBPR108
metformin hydrochloride
placepo
Sponsored by
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring DBPR108, Dipeptidyl peptidase-4 (DPP4) inhibitors, metformin hydrochloride

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of type 2 diabetes according to World Health Organization (1999) diabetes diagnosis standard;
  • Age 18-75 years, men and women;
  • BMI 19-35 kg/m2;
  • HbA1c 7.0%-9.5%;
  • Before screening, a stable Metformin dose(≥1000mg/day)should be maintained for at least 8 weeks.
  • Signed informed consent from the patient;
  • Agree to use contraceptive measures from the date of signing the informed consent to 1 month after the end of the last medication.

Exclusion Criteria:

  • FPG > 13.9 mmol/L;
  • Insulin treatment required in the investigator's opinion;
  • Administration of antidiabetic drugs (except for metformin) including insulin, rosiglitazone, pioglitazone, DPP-4 inhibitor, Glucagon like peptide-1 (GLP-1) receptor agonist for 8 weeks before screening;
  • Acute complications of diabetes (including diabetic ketosis and ketoacidosis, hyperosmotic nonketotic diabetic coma, lactic acidosis and hypoglycemia coma);
  • Severe hypoglycemia;
  • Serious diabetic complications (such as diabetic foot, etc.);
  • History of acute or chronic pancreatitis, or related diseases that are most common cause of acute pancreatitis (such as recurrent cholelithiasis, etc.);
  • History of being allergic to DPP-4 inhibitors;
  • Untreated hyperthyroidism and other diseases which may cause secondary hyperglycemia;
  • Previous treatment with glucocorticoids (except for external use and inhalation) within 4 weeks before screening or may be used for more than 14 consecutive days during the study;
  • Inflammatory bowel disease, partial intestinal obstruction or chronic bowel disease related to obvious digestive and absorption disorders;
  • Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) > 3*upper limit of normal (ULN), or total bilirubin > 1.5ULN;
  • Abnormal renal function;
  • White blood cells (WBC) < 3.0109/l, neutrophil count of peripheral blood < 1.5109/l, hemoglobin < 100g / L, triglyceride > 5.7 mmol/l;
  • HBsAg, HBeAg or HBcAb positive, or any one of hepatitis C antibody, anti-HIV antibody and nonspecific antibody of Treponema pallidum positive;
  • Pregnant or lactating women;
  • History of alcohol or drug abuse;
  • Participation in other clinical trials or administration of any other investigational drugs or devices within 3 months before screening;
  • Significant unstable diseases;
  • Any condition that in the investigator's opinion might render the patient unable to participate the trial.

Sites / Locations

  • Peking Union Medical College Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

metformin hydrochloride+DBPR108

metformin hydrochloride+placepo

Arm Description

metformin hydrochloride 500 mg+DBPR108 100 mg

metformin hydrochloride 500 mg+placebo 100 mg

Outcomes

Primary Outcome Measures

Change in HbA1c (%) from baseline to week 24
The change of HbA1c from baseline to 24 weeks compared with metformin hydrochloride + placebo

Secondary Outcome Measures

Percentage of HbA1c ≤ 6.5%
Proportion of patients achieving HbA1c ≤ 6.5% at week 24
Percentage of HbA1c ≤ 7%
Proportion of patients achieving HbA1c ≤ 7% at week 24
Change in HbA1c (%) from baseline to week 12
The change of HbA1c from baseline to 12 weeks compared with metformin hydrochloride + placebo
Change in fasting plasma glucose (FPG) from baseline to week 12 and week 24
The change in FPG from baseline to week 12 and week 24 compared with metformin hydrochloride + placebo
Change in 2h-postprandial plasma glucose (2h-PPG) from baseline to week 12 and week 24
The change in 2h-PPG from baseline to week 12 and week 24 compared with metformin hydrochloride + placebo
Change in body weight from baseline to week 12 and week 24
The change in body weight from baseline to week 12 and week 24 compared with metformin hydrochloride +placebo

Full Information

First Posted
January 3, 2020
Last Updated
June 23, 2021
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04218734
Brief Title
A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM
Official Title
A Multicenter, Randomized, Double-blind, Parallel Controlled Phase III Clinical Trial of DBRP108 in Combination With Metformin Hydrochloride in the Treatment of Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
January 14, 2020 (Actual)
Primary Completion Date
June 3, 2021 (Actual)
Study Completion Date
June 3, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study aims to evaluate the efficacy and safety of DBPR108 tablets in combination with metformin hydrochloride in the treatment of type 2 diabetes mellitus. A total of 210 subjects will be randomly assigned in a ratio of 2:1 to receive metformin hydrochloride plus DBPR108 or metformin hydrochloride plus placebo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
DBPR108, Dipeptidyl peptidase-4 (DPP4) inhibitors, metformin hydrochloride

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
214 (Actual)

8. Arms, Groups, and Interventions

Arm Title
metformin hydrochloride+DBPR108
Arm Type
Experimental
Arm Description
metformin hydrochloride 500 mg+DBPR108 100 mg
Arm Title
metformin hydrochloride+placepo
Arm Type
Placebo Comparator
Arm Description
metformin hydrochloride 500 mg+placebo 100 mg
Intervention Type
Drug
Intervention Name(s)
DBPR108
Intervention Description
DBPR108: 100 mg, once daily for 24 weeks.
Intervention Type
Drug
Intervention Name(s)
metformin hydrochloride
Intervention Description
metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.
Intervention Type
Drug
Intervention Name(s)
placepo
Intervention Description
placebo:100 mg, once daily for 24 weeks.
Primary Outcome Measure Information:
Title
Change in HbA1c (%) from baseline to week 24
Description
The change of HbA1c from baseline to 24 weeks compared with metformin hydrochloride + placebo
Time Frame
baseline, 24 weeks
Secondary Outcome Measure Information:
Title
Percentage of HbA1c ≤ 6.5%
Description
Proportion of patients achieving HbA1c ≤ 6.5% at week 24
Time Frame
24 weeks
Title
Percentage of HbA1c ≤ 7%
Description
Proportion of patients achieving HbA1c ≤ 7% at week 24
Time Frame
24 weeks
Title
Change in HbA1c (%) from baseline to week 12
Description
The change of HbA1c from baseline to 12 weeks compared with metformin hydrochloride + placebo
Time Frame
baseline, 12 weeks
Title
Change in fasting plasma glucose (FPG) from baseline to week 12 and week 24
Description
The change in FPG from baseline to week 12 and week 24 compared with metformin hydrochloride + placebo
Time Frame
Baseline, 12 weeks and 24 weeks
Title
Change in 2h-postprandial plasma glucose (2h-PPG) from baseline to week 12 and week 24
Description
The change in 2h-PPG from baseline to week 12 and week 24 compared with metformin hydrochloride + placebo
Time Frame
Baseline, 12 weeks and 24 weeks
Title
Change in body weight from baseline to week 12 and week 24
Description
The change in body weight from baseline to week 12 and week 24 compared with metformin hydrochloride +placebo
Time Frame
Baseline, 12 weeks and 24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of type 2 diabetes according to World Health Organization (1999) diabetes diagnosis standard; Age 18-75 years, men and women; BMI 19-35 kg/m2; HbA1c 7.0%-9.5%; Before screening, a stable Metformin dose(≥1000mg/day)should be maintained for at least 8 weeks. Signed informed consent from the patient; Agree to use contraceptive measures from the date of signing the informed consent to 1 month after the end of the last medication. Exclusion Criteria: FPG > 13.9 mmol/L; Insulin treatment required in the investigator's opinion; Administration of antidiabetic drugs (except for metformin) including insulin, rosiglitazone, pioglitazone, DPP-4 inhibitor, Glucagon like peptide-1 (GLP-1) receptor agonist for 8 weeks before screening; Acute complications of diabetes (including diabetic ketosis and ketoacidosis, hyperosmotic nonketotic diabetic coma, lactic acidosis and hypoglycemia coma); Severe hypoglycemia; Serious diabetic complications (such as diabetic foot, etc.); History of acute or chronic pancreatitis, or related diseases that are most common cause of acute pancreatitis (such as recurrent cholelithiasis, etc.); History of being allergic to DPP-4 inhibitors; Untreated hyperthyroidism and other diseases which may cause secondary hyperglycemia; Previous treatment with glucocorticoids (except for external use and inhalation) within 4 weeks before screening or may be used for more than 14 consecutive days during the study; Inflammatory bowel disease, partial intestinal obstruction or chronic bowel disease related to obvious digestive and absorption disorders; Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) > 3*upper limit of normal (ULN), or total bilirubin > 1.5ULN; Abnormal renal function; White blood cells (WBC) < 3.0109/l, neutrophil count of peripheral blood < 1.5109/l, hemoglobin < 100g / L, triglyceride > 5.7 mmol/l; HBsAg, HBeAg or HBcAb positive, or any one of hepatitis C antibody, anti-HIV antibody and nonspecific antibody of Treponema pallidum positive; Pregnant or lactating women; History of alcohol or drug abuse; Participation in other clinical trials or administration of any other investigational drugs or devices within 3 months before screening; Significant unstable diseases; Any condition that in the investigator's opinion might render the patient unable to participate the trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kun Lou
Organizational Affiliation
Department of medicine, CSPC clinical development division
Official's Role
Study Director
Facility Information:
Facility Name
Peking Union Medical College Hospital
City
Beijing
Country
China

12. IPD Sharing Statement

Learn more about this trial

A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM

We'll reach out to this number within 24 hrs